Bellicum Pharmaceuticals Company Profile (NASDAQ:BLCM)

About Bellicum Pharmaceuticals (NASDAQ:BLCM)

Bellicum Pharmaceuticals logoBellicum Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system. The Company is developing next-generation product candidates in the areas of cellular immunotherapy, including hematopoietic stem cell transplantation (HSCT), chimeric antigen receptors (CAR) T cells therapy and T-cell receptor (TCR) cell therapies. The Company's product candidates include BPX-501, BPX-601 and BPX-701. The Company's CID-based technologies include CaspaCIDe and GoCAR-T. It is evaluating BPX-501 in various Phase I/II clinical trials in adults and pediatric patients with leukemias, lymphomas and genetic blood diseases in the United States and Europe.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:BLCM
  • CUSIP: N/A
  • Web: www.bellicum.com
Capitalization:
  • Market Cap: $408.82 million
  • Outstanding Shares: 33,103,000
Average Prices:
  • 50 Day Moving Avg: $13.00
  • 200 Day Moving Avg: $14.47
  • 52 Week Range: $9.37 - $23.11
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -4.56
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $423,999.00
  • Price / Sales: 964.21
  • Book Value: $4.33 per share
  • Price / Book: 2.85
Profitability:
  • EBIDTA: ($72,020,000.00)
  • Net Margins: -19,399.12%
  • Return on Equity: -49.65%
  • Return on Assets: -42.92%
Debt:
  • Debt-to-Equity Ratio: 0.18%
  • Current Ratio: 12.41%
  • Quick Ratio: 12.41%
Misc:
  • Average Volume: 670,895 shs.
  • Beta: 1.48
  • Short Ratio: 3.75
 

Frequently Asked Questions for Bellicum Pharmaceuticals (NASDAQ:BLCM)

What is Bellicum Pharmaceuticals' stock symbol?

Bellicum Pharmaceuticals trades on the NASDAQ under the ticker symbol "BLCM."

How were Bellicum Pharmaceuticals' earnings last quarter?

Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) released its earnings results on Monday, May, 8th. The company reported ($0.80) earnings per share for the quarter, missing analysts' consensus estimates of ($0.70) by $0.10. The firm had revenue of $0.13 million for the quarter, compared to the consensus estimate of $0.09 million. Bellicum Pharmaceuticals had a negative return on equity of 49.65% and a negative net margin of 19,399.12%. The company's revenue was up 39.1% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.56) EPS. View Bellicum Pharmaceuticals' Earnings History.

Where is Bellicum Pharmaceuticals' stock going? Where will Bellicum Pharmaceuticals' stock price be in 2017?

8 equities research analysts have issued twelve-month price targets for Bellicum Pharmaceuticals' stock. Their forecasts range from $18.00 to $32.00. On average, they anticipate Bellicum Pharmaceuticals' share price to reach $26.81 in the next year. View Analyst Ratings for Bellicum Pharmaceuticals.

What are analysts saying about Bellicum Pharmaceuticals stock?

Here are some recent quotes from research analysts about Bellicum Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "Bellicum Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. It is focused on discovering and developing cellular immunotherapies for various forms of cancer, including both hematological and solid tumors, as well as orphan inherited blood disorders. The Company's lead clinical product candidate is BPX-501, an adjunct T-cell therapy in multiple Phase I/II clinical trials. It is also developing BPX-201, a dendritic cell cancer vaccine, which is in a Phase I clinical trial for the treatment of metastatic castrate-resistant prostate cancer. Bellicum Pharmaceuticals, Inc. is based in Houston, Texas. " (3/16/2017)
  • 2. Cantor Fitzgerald analysts commented, "Following Bellicum's 4Q16 earnings conference call, we are reiterating our Overweight rating and $32 price target. Bellicum provided several updates outlining its plans for 2017, including: 1) progress in its current BP-004 trial with BPX-501 in malignant and non-malignant pediatric transplant patients, 2) greater clarity from the FDA on the development path of BPX-501 in the U.S., and 3) updates on its expanding CAR and TCR oncology programs. Looking forward, we expect additional updated data at the European Hematology Association (EHA) meeting being held in June and an update on the finalized U.S. registration trial design in mid-2017." (3/14/2017)
  • 3. Jefferies Group LLC analysts commented, "BLCM presented long term data consistent with the ASH 2016 readout, demonstrating low rates of GvHD and relapse. One theme of the meeting we found interesting was the ongoing debate on whether T cells are necessary to prevent BMT complications and relapse. Further, conversations with docs highlighted the discordant strategies for GvHD prevention." (2/27/2017)

Are investors shorting Bellicum Pharmaceuticals?

Bellicum Pharmaceuticals saw a increase in short interest during the month of April. As of April 28th, there was short interest totalling 3,579,907 shares, an increase of 9.0% from the April 13th total of 3,284,379 shares. Based on an average trading volume of 518,829 shares, the short-interest ratio is currently 6.9 days.

Who are some of Bellicum Pharmaceuticals' key competitors?

When did Bellicum Pharmaceuticals IPO?

(BLCM) raised $101 million in an initial public offering (IPO) on Thursday, December 18th 2014. The company issued 6,300,000 shares at a price of $15.00-$17.00 per share. Jefferies, Citigroup and Piper Jaffray acted as the underwriters for the IPO and Trout Capital was co-manager.

Who owns Bellicum Pharmaceuticals stock?

Bellicum Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BAKER BROS. ADVISORS LP (15.20%), FMR LLC (10.53%), JPMorgan Chase & Co. (8.24%), Vanguard Group Inc. (3.91%), Foresite Capital Management III LLC (3.38%) and Kennedy Capital Management Inc. (2.33%). Company insiders that own Bellicum Pharmaceuticals stock include Alan A Musso, Annemarie Moseley, Bros Advisors Lp Baker, David M Spencer, Ken Moseley, Kevin M Slawin and Thomas J Farrell. View Institutional Ownership Trends for Bellicum Pharmaceuticals.

Who sold Bellicum Pharmaceuticals stock? Who is selling Bellicum Pharmaceuticals stock?

Bellicum Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Eventide Asset Management LLC, Morgan Stanley, Highbridge Capital Management LLC, Credit Suisse AG, Suffolk Capital Management LLC, TD Asset Management Inc. and ProShare Advisors LLC. Company insiders that have sold Bellicum Pharmaceuticals stock in the last year include Alan A Musso, Annemarie Moseley, David M Spencer, Ken Moseley and Kevin M Slawin. View Insider Buying and Selling for Bellicum Pharmaceuticals.

Who bought Bellicum Pharmaceuticals stock? Who is buying Bellicum Pharmaceuticals stock?

Bellicum Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including Foresite Capital Management III LLC, LMR Partners LLP, Sphera Funds Management LTD., Vanguard Group Inc., Monashee Investment Management LLC, Kennedy Capital Management Inc., Renaissance Technologies LLC and JPMorgan Chase & Co.. View Insider Buying and Selling for Bellicum Pharmaceuticals.

How do I buy Bellicum Pharmaceuticals stock?

Shares of Bellicum Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Bellicum Pharmaceuticals stock cost?

One share of Bellicum Pharmaceuticals stock can currently be purchased for approximately $12.35.

Analyst Ratings

Consensus Ratings for Bellicum Pharmaceuticals (NASDAQ:BLCM) (?)
Ratings Breakdown: 8 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $26.81 (117.11% upside)

Analysts' Ratings History for Bellicum Pharmaceuticals (NASDAQ:BLCM)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/10/2017Cantor FitzgeraldReiterated RatingOverweight$32.00LowView Rating Details
5/9/2017Jefferies Group LLCLower Price TargetBuy$19.00 -> $18.00HighView Rating Details
3/8/2017Wells Fargo & CoInitiated CoverageOutperform -> Outperform$29.50HighView Rating Details
12/1/2016Raymond James Financial, Inc.Initiated CoverageOutperform$29.00N/AView Rating Details
11/30/2016Ladenburg Thalmann Financial ServicesInitiated CoverageBuy$31.00N/AView Rating Details
8/9/2016Piper Jaffray CompaniesReiterated RatingOverweight$25.00 -> $31.00N/AView Rating Details
8/9/2016Citigroup IncUpgradeNeutral -> Buy$24.00N/AView Rating Details
6/2/2016SunTrust Banks, Inc.Initiated CoverageBuy$20.00N/AView Rating Details
9/11/2015GuggenheimUpgradeNeutral -> Buy$38.00N/AView Rating Details
(Data available from 5/22/2015 forward)

Earnings

Earnings History for Bellicum Pharmaceuticals (NASDAQ:BLCM)
Earnings by Quarter for Bellicum Pharmaceuticals (NASDAQ:BLCM)
Earnings History by Quarter for Bellicum Pharmaceuticals (NASDAQ:BLCM)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/8/2017Q1 2017($0.70)($0.80)$0.09 million$0.13 millionViewN/AView Earnings Details
3/13/2017Q4 2016($0.71)($0.74)$0.10 million$0.08 millionViewN/AView Earnings Details
11/9/2016Q3($0.63)($0.66)$0.09 million$0.11 millionViewN/AView Earnings Details
8/8/2016Q216($0.57)($0.61)$0.10 million$0.10 millionViewListenView Earnings Details
3/14/2016Q415($0.44)($0.63)$2.00 million$0.03 millionViewListenView Earnings Details
11/9/2015Q315($0.38)($0.51)$0.18 million$0.06 millionViewN/AView Earnings Details
8/13/2015Q215($0.49)($0.40)$0.23 million$0.08 millionViewListenView Earnings Details
5/11/2015Q1($0.22)($0.30)$0.50 million$0.11 millionViewN/AView Earnings Details
3/11/2015Q4($11.79)($2.02)$0.60 million$0.02 millionViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Bellicum Pharmaceuticals (NASDAQ:BLCM)
2017 EPS Consensus Estimate: ($2.73)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($0.72)($0.71)($0.72)
Q2 20172($0.67)($0.63)($0.65)
Q3 20172($0.70)($0.63)($0.67)
Q4 20172($0.76)($0.63)($0.70)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Bellicum Pharmaceuticals (NASDAQ:BLCM)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Bellicum Pharmaceuticals (NASDAQ:BLCM)
Insider Ownership Percentage: 23.30%
Institutional Ownership Percentage: 68.87%
Insider Trades by Quarter for Bellicum Pharmaceuticals (NASDAQ:BLCM)
Institutional Ownership by Quarter for Bellicum Pharmaceuticals (NASDAQ:BLCM)
Insider Trades by Quarter for Bellicum Pharmaceuticals (NASDAQ:BLCM)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
3/24/2017Bros. Advisors Lp BakerMajor ShareholderBuy166,666$12.00$1,999,992.00View SEC Filing  
2/7/2017Kevin M SlawinDirectorSell30,000$12.54$376,200.00View SEC Filing  
12/15/2016Kevin M SlawinInsiderSell30,000$15.45$463,500.00View SEC Filing  
12/5/2016David M SpencerInsiderSell5,000$20.00$100,000.00View SEC Filing  
12/1/2016Annemarie MoseleyCOOSell25,000$17.54$438,500.00View SEC Filing  
11/28/2016Alan A. MussoCFOSell29,300$19.51$571,643.00View SEC Filing  
9/23/2016Ken MoseleyVPSell11,800$20.10$237,180.00View SEC Filing  
9/23/2016Kevin M SlawinInsiderSell23,416$20.12$471,129.92View SEC Filing  
9/20/2016David M SpencerInsiderSell2,500$20.01$50,025.00View SEC Filing  
9/20/2016Ken MoseleyVPSell2,200$20.01$44,022.00View SEC Filing  
8/15/2016Ken MoseleyVPSell1,000$20.00$20,000.00View SEC Filing  
8/15/2016Kevin M SlawinInsiderSell67,000$19.31$1,293,770.00View SEC Filing  
7/27/2016David M. SpencerInsiderSell10,000$15.00$150,000.00View SEC Filing  
7/18/2016Kevin M SlawinCTOSell2,719$13.99$38,038.81View SEC Filing  
7/15/2016Kevin M SlawinCTOSell22,281$13.72$305,695.32View SEC Filing  
6/2/2016Annemarie MoseleyCOOSell25,000$13.00$325,000.00View SEC Filing  
6/2/2016Ken MoseleyVPSell15,000$13.00$195,000.00View SEC Filing  
4/22/2016Kevin M SlawinCTOSell55,000$11.43$628,650.00View SEC Filing  
1/4/2016Annemarie MoseleyCOOSell35,000$19.07$667,450.00View SEC Filing  
12/1/2015David M SpencerInsiderSell5,000$22.95$114,750.00View SEC Filing  
11/24/2015Alan A MussoCFOSell29,300$22.34$654,562.00View SEC Filing  
11/2/2015Ken MoseleyVPSell15,000$13.00$195,000.00View SEC Filing  
10/1/2015Thomas J FarrellCEOSell2,500$14.58$36,450.00View SEC Filing  
9/11/2015David M SpencerInsiderSell5,000$19.00$95,000.00View SEC Filing  
9/1/2015Thomas J FarrellCEOSell2,500$16.78$41,950.00View SEC Filing  
7/15/2015Kevin M SlawinCTOSell6,000$20.00$120,000.00View SEC Filing  
6/16/2015David M SpencerInsiderSell20,000$22.96$459,200.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Bellicum Pharmaceuticals (NASDAQ:BLCM)
Latest Headlines for Bellicum Pharmaceuticals (NASDAQ:BLCM)
Source:
DateHeadline
streetinsider.com logoBellicum Pharma (BLCM) Reports Clinical Presentations at EHA - StreetInsider.com
www.streetinsider.com - May 18 at 3:53 PM
streetinsider.com logoBellicum Pharma (BLCM) Reports Clinical Presentations at EHA
www.streetinsider.com - May 18 at 11:41 AM
globenewswire.com logoBellicum Pharmaceuticals Announces Management Changes - GlobeNewswire (press release)
globenewswire.com - May 16 at 4:02 PM
finance.yahoo.com logoBellicum Pharmaceuticals Announces Management Changes
finance.yahoo.com - May 16 at 12:36 PM
finance.yahoo.com logoHouston pharmaceutical company announces C-level changes
finance.yahoo.com - May 16 at 12:36 PM
americanbankingnews.com logoBellicum Pharmaceuticals Inc (BLCM) Short Interest Update
www.americanbankingnews.com - May 15 at 9:16 AM
americanbankingnews.com logoAnalysts Offer Predictions for Bellicum Pharmaceuticals Inc's FY2017 Earnings (BLCM)
www.americanbankingnews.com - May 15 at 8:50 AM
prnewswire.com logoUveal Melanoma H1 2017 Pipeline Stages by Companies and Drugs in Market Report at ReportsnReports.com
www.prnewswire.com - May 12 at 9:33 PM
finance.yahoo.com logoBellicum Pharmaceuticals, Inc. – Value Analysis (NASDAQ:BLCM) : May 11, 2017
finance.yahoo.com - May 11 at 9:32 PM
americanbankingnews.com logoSunTrust Banks Comments on Bellicum Pharmaceuticals Inc's Q2 2017 Earnings (BLCM)
www.americanbankingnews.com - May 11 at 9:14 AM
americanbankingnews.com logoBellicum Pharmaceuticals Inc to Post Q2 2017 Earnings of ($0.63) Per Share, Jefferies Group Forecasts (BLCM)
www.americanbankingnews.com - May 11 at 9:14 AM
americanbankingnews.com logoSunTrust Banks Weighs in on Bellicum Pharmaceuticals Inc's FY2021 Earnings (BLCM)
www.americanbankingnews.com - May 10 at 3:40 PM
americanbankingnews.com logoBellicum Pharmaceuticals' (BLCM) Overweight Rating Reiterated at Cantor Fitzgerald
www.americanbankingnews.com - May 10 at 11:06 AM
americanbankingnews.com logoBellicum Pharmaceuticals Inc (BLCM) Stock Rating Reaffirmed by Jefferies Group LLC
www.americanbankingnews.com - May 10 at 12:16 AM
benzinga.com logoBellicum Pharmaceuticals Q1 Miss Doesn't Matter, As Long As Pipeline Remains On Track
www.benzinga.com - May 9 at 3:58 PM
finance.yahoo.com logoBellicum Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : BLCM-US : May 9, 2017
finance.yahoo.com - May 9 at 3:58 PM
americanbankingnews.com logoBellicum Pharmaceuticals Inc (BLCM) Issues Quarterly Earnings Results
www.americanbankingnews.com - May 8 at 11:32 PM
americanbankingnews.com logoBellicum Pharmaceuticals Inc (BLCM) Issues Earnings Results
www.americanbankingnews.com - May 8 at 9:40 PM
cnbc.com logoBellicum Pharmaceuticals posts 1Q loss
www.cnbc.com - May 8 at 8:50 PM
finance.yahoo.com logoBellicum Pharmaceuticals Reports First Quarter 2017 Financial Results
finance.yahoo.com - May 8 at 8:50 PM
americanbankingnews.com logoBellicum Pharmaceuticals Inc (BLCM) Scheduled to Post Quarterly Earnings on Monday
www.americanbankingnews.com - May 6 at 12:16 AM
americanbankingnews.com logoBellicum Pharmaceuticals Inc (BLCM) to Release Earnings on Monday
www.americanbankingnews.com - May 5 at 11:54 PM
americanbankingnews.com logo$80,000.00 in Sales Expected for Bellicum Pharmaceuticals Inc (BLCM) This Quarter
www.americanbankingnews.com - May 4 at 11:32 AM
americanbankingnews.com logoBellicum Pharmaceuticals (BLCM) Earning Somewhat Critical Media Coverage, Study Finds
www.americanbankingnews.com - May 3 at 9:48 AM
americanbankingnews.com logoBellicum Pharmaceuticals Inc (BLCM) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - May 3 at 8:40 AM
americanbankingnews.com logoBellicum Pharmaceuticals Inc (BLCM) Expected to Announce Earnings of -$0.67 Per Share
www.americanbankingnews.com - May 2 at 7:58 PM
americanbankingnews.com logoBellicum Pharmaceuticals (BLCM) Earning Somewhat Critical Media Coverage, AlphaOne Reports
www.americanbankingnews.com - April 29 at 10:02 AM
finance.yahoo.com logoBellicum Pharmaceuticals to Present at the Deutsche Bank 42nd Annual Health Care Conference
finance.yahoo.com - April 26 at 12:55 PM
americanbankingnews.com logoBellicum Pharmaceuticals (BLCM) Receiving Somewhat Positive Media Coverage, Analysis Shows
www.americanbankingnews.com - April 20 at 4:03 PM
americanbankingnews.com logoBellicum Pharmaceuticals (BLCM) Earns News Sentiment Score of -0.16
www.americanbankingnews.com - April 17 at 2:08 PM
americanbankingnews.com logoBellicum Pharmaceuticals Inc (BLCM) Expected to Post Earnings of -$0.67 Per Share
www.americanbankingnews.com - April 11 at 4:15 PM
finance.yahoo.com logoBellicum Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : BLCM-US : April 11, 2017
finance.yahoo.com - April 11 at 4:01 PM
americanbankingnews.com logoBellicum Pharmaceuticals Inc (BLCM) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - April 7 at 6:31 PM
finance.yahoo.com logoBellicum Pharmaceuticals Announces Late-Breaking Presentation of Dual-Switch CAR-T / TCR Technology at AACR
finance.yahoo.com - April 7 at 8:30 AM
finance.yahoo.com logoBiotech Movers: Sarepta, Bellicum, Novavax
finance.yahoo.com - April 7 at 8:30 AM
finance.yahoo.com logoThe First CAR-T Drugs Have Left the Gate
finance.yahoo.com - April 7 at 8:30 AM
globenewswire.com logoBellicum Pharmaceuticals Announces Closing of Public Offering - GlobeNewswire (press release)
globenewswire.com - March 31 at 9:08 PM
finance.yahoo.com logoBellicum Pharmaceuticals Announces Closing of Public Offering
finance.yahoo.com - March 30 at 4:21 PM
americanbankingnews.com logoBellicum Pharmaceuticals Inc (BLCM) Major Shareholder Bros. Advisors Lp Baker Acquires 166,666 Shares
www.americanbankingnews.com - March 29 at 9:11 AM
baystreet.ca logoBellicum Pharmaceuticals (BLCM) Drops on Public Offering
www.baystreet.ca - March 24 at 8:17 PM
biz.yahoo.com logoBELLICUM PHARMACEUTICALS, INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits
biz.yahoo.com - March 24 at 8:17 PM
streetinsider.com logoBellicum Pharma (BLCM) Prices 5M Shares at $12
www.streetinsider.com - March 24 at 2:24 AM
us.rd.yahoo.com logoBellicum Pharmaceuticals Announces Pricing of Public Offering of Common Stock
us.rd.yahoo.com - March 24 at 2:24 AM
americanbankingnews.com logoCantor Fitzgerald Comments on Bellicum Pharmaceuticals Inc's FY2017 Earnings (BLCM)
www.americanbankingnews.com - March 23 at 9:32 AM
streetinsider.com logoAfter-Hours Stock Movers 03/22: (HTGM) (BEBE) (FIVE) (PVH) Higher; (HTBX) (RARE) (BLCM) Lower (more...)
www.streetinsider.com - March 22 at 8:39 PM
rttnews.com logoBellicum Pharmaceuticals Inc. (BLCM) Is Down After Offering Announcement
www.rttnews.com - March 22 at 8:39 PM
us.rd.yahoo.com logoBellicum Pharmaceuticals Announces Proposed Public Offering of Common Stock
us.rd.yahoo.com - March 22 at 8:39 PM
finance.yahoo.com logoBELLICUM PHARMACEUTICALS, INC Financials
finance.yahoo.com - March 17 at 3:15 PM
thestreet.com logo5 Stocks Trending Close to Major Breakouts
www.thestreet.com - March 17 at 3:15 PM
americanbankingnews.com logoBellicum Pharmaceuticals Inc (BLCM) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - March 16 at 10:21 PM

Social

Bellicum Pharmaceuticals (BLCM) Chart for Monday, May, 22, 2017

This page was last updated on 5/22/2017 by MarketBeat.com Staff